Movymia

teriparatide

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Movymia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Movymia.

For practical information about using Movymia, patients should read the package leaflet or contact their doctor or pharmacist.

What is Movymia and what is it used for?

Movymia is a medicine used for the treatment of osteoporosis (a disease that makes bones fragile) in:

  • women who have been through the menopause. In these patients, Movymia has been shown to significantly reduce vertebral (spine) and non-vertebral fractures (broken bones), but not those of the hip;
  • men who are at an increased risk of fractures;
  • men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid).

Movymia contains the active substance teriparatide.

Movymia is a ‘biosimilar medicine’. This means that Movymia is highly similar to a biological medicine (also known as the ‘reference medicine’) that is already authorised in the European Union (EU). The reference medicine for Movymia is Forsteo. For more information on biosimilar medicines, see the question-and-answer document here.

How is Movymia used?

Movymia is available as a solution for injection in cartridges (containing 600 micrograms of teriparatide) intended to be used with ServoPen Fix system. The recommended dose is 20 micrograms of Movymia given once a day as an injection under the skin of the thigh or abdomen (belly). Patients may inject themselves once they have been trained.

Patients should receive calcium and vitamin D supplements if they do not get enough from their diet. Movymia can be used for up to two years. The two-year course of Movymia should be given only once during a patient’s lifetime.

The medicine can only be obtained with a prescription.

How does Movymia work?

Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become less dense and more likely to break. In women, osteoporosis is more common after the menopause, when the levels of the female hormone oestrogen fall. Osteoporosis can also occur as a side effect of glucocorticoid treatment in men and women.

The active substance in Movymia, teriparatide, is identical to part of the human parathyroid hormone. It acts like the hormone to stimulate bone formation by acting on osteoblasts (bone-forming cells). It also increases the absorption of calcium from food and prevents too much calcium being lost in the urine.

What benefits of Movymia have been shown in studies?

Laboratory studies comparing Movymia with Forsteo have shown that the active substance in Movymia is highly similar to that in Forsteo in terms of structure, purity and biological activity.

Because Movymia is a biosimilar medicine, the studies on effectiveness and safety of teriparatide carried out with Forsteo do not need to be repeated for Movymia. A study in 54 healthy women has shown that the same doses of the two medicines given by injection under the skin produced similar levels of the active substance teriparatide in the body. Further, Movymia and Forsteo produced similar effects on calcium levels in the blood.

What are the risks associated with Movymia?

The most common side effect with Movymia (seen in more than 1 patient in 10) is pain in the arms or legs. For the full list of all side effects reported with Movymia, see the package leaflet.

Movymia must not be used in patients who have other bone diseases such as Paget’s disease, bone cancer or bone metastases (cancer that has spread to the bone), patients who have had radiation therapy of the skeleton, or patients who have hypercalcaemia (high blood calcium levels), unexplained high levels of alkaline phosphatase (an enzyme) or severe kidney disease. Movymia must not be used during pregnancy or breastfeeding. For the full list of restrictions, see the package leaflet.

Why is Movymia approved?

The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered evidence showing that Movymia has a highly similar structure, purity and biological activity to Forsteo and is distributed in the body in the same way. This was considered sufficient to conclude that Movymia will behave in the same way in terms of effectiveness and safety. Thus, as for Forsteo, the benefit outweighs the identified risks and the Committee recommended that Movymia be given marketing authorisation.

What measures are being taken to ensure the safe and effective use of Movymia?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Movymia have been included in the summary of product characteristics and the package leaflet.

Other information about Movymia

The European Commission granted a marketing authorisation valid throughout the European Union for Movymia on 11 January 2017.

For more information about treatment with Movymia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Movymia : EPAR - Summary for the public BG = bălgarski 2017-03-16  
Movymia : EPAR - Summary for the public ES = español 2017-03-16  
Movymia : EPAR - Summary for the public CS = čeština 2017-03-16  
Movymia : EPAR - Summary for the public DA = dansk 2017-03-16  
Movymia : EPAR - Summary for the public DE = Deutsch 2017-03-16  
Movymia : EPAR - Summary for the public ET = eesti keel 2017-03-16  
Movymia : EPAR - Summary for the public EL = elliniká 2017-03-16  
Movymia : EPAR - Summary for the public EN = English 2017-03-16  
Movymia : EPAR - Summary for the public FR = français 2017-03-16  
Movymia : EPAR - Summary for the public IT = italiano 2017-03-16  
Movymia : EPAR - Summary for the public LV = latviešu valoda 2017-03-16  
Movymia : EPAR - Summary for the public LT = lietuvių kalba 2017-03-16  
Movymia : EPAR - Summary for the public HU = magyar 2017-03-16  
Movymia : EPAR - Summary for the public MT = Malti 2017-03-16  
Movymia : EPAR - Summary for the public NL = Nederlands 2017-03-16  
Movymia : EPAR - Summary for the public PL = polski 2017-03-16  
Movymia : EPAR - Summary for the public PT = português 2017-03-16  
Movymia : EPAR - Summary for the public RO = română 2017-03-16  
Movymia : EPAR - Summary for the public SK = slovenčina 2017-03-16  
Movymia : EPAR - Summary for the public SL = slovenščina 2017-03-16  
Movymia : EPAR - Summary for the public FI = suomi 2017-03-16  
Movymia : EPAR - Summary for the public SV = svenska 2017-03-16  
Movymia : EPAR - Summary for the public HR = Hrvatski 2017-03-16  

This EPAR was last updated on 05/05/2017 .

Authorisation details

Product details

Product details for Movymia
NameMovymia
Agency product numberEMEA/H/C/004368
Active substance

teriparatide

International non-proprietary name (INN) or common name

teriparatide

Therapeutic area Osteoporosis
Anatomical therapeutic chemical (ATC) code H05AA02
Biosimilar

A biosimilar medicine is a medicine which is similar to a biological medicine that has already been authorised (the ‘biological reference medicine’). The active substance of a biosimilar medicine similar to the one of the biological reference medicine. Biosimilar and biological reference medicines are used in general at the same dose to treat the same disease.

Publication details

Publication details for Movymia
Marketing-authorisation holder

STADA Arzneimittel AG

Revision1
Date of issue of marketing authorisation valid throughout the European Union11/01/2017

Contact address:

STADA Arzneimittel AG
Stadastrasse 2-18
Bad Vilbel
Hessen 61118
Germany

Product information

Product information

05/04/2017  Movymia -EMEA/H/C/004368 -IB/0002/G

Name Language First published Last updated
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05
Movymia : EPAR - Product Information HR = Hrvatski 2017-03-16 2017-05-05

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  
Movymia : EPAR - All Authorised presentations HR = Hrvatski 2017-03-16  

Pharmacotherapeutic group

Calcium homeostasis

Therapeutic indication

Movymia is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Movymia : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 2017-05-05  

Initial marketing-authorisation documents

Name Language First published Last updated
Movymia : EPAR - Public assessment report HR = Hrvatski 2017-03-16  
CHMP summary of positive opinion for Movymia HR = Hrvatski 2016-11-11  

Authorised

This medicine is approved for use in the European Union

Related content